{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T10:29:47Z","timestamp":1776853787661,"version":"3.51.2"},"reference-count":33,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T00:00:00Z","timestamp":1723593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Anti-human immunodeficiency virus (HIV) broadly neutralizing antibodies (bNAbs) offer a promising approach for the treatment of HIV-1. The current paradigm for antibody therapy involves passive antibody transfer, requiring regular delivery of bNAbs in treating chronic diseases such as HIV-1. An alternative strategy is to use AAV-mediated gene transfer to enable in vivo production of desirable anti-HIV-1 antibodies. In this study, we investigated two sets of triple combinations of AAV9-vectors encoding different bNAbs: N6, 10E8, 10-1074 (CombiMab1), and VRC07-523, PGDM1400, 10-1074 (CombiMab2). We used CBAxC57Bl and C57BL\/6 mouse models to characterize rAAV-induced antibody expression and to evaluate the neutralization capacity of mouse sera against a global panel of HIV-1 viral strains. rAAV9-mediated IgG expression varied between bNAb clones and mouse strains, with C57BL\/6 mice exhibiting higher bNAb titers following rAAV delivery. Although CombiMab2 treatment elicited a higher IgG titer than CombiMab1, both combinations resulted in neutralization of all the viral strains from the global HIV-1 panel. Our data highlight the potential of AAV vectors as a long-term option for HIV-1 therapy.<\/jats:p>","DOI":"10.3390\/v16081296","type":"journal-article","created":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T09:20:51Z","timestamp":1723627251000},"page":"1296","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Triple Combinations of AAV9-Vectors Encoding Anti-HIV bNAbs Provide Long-Term In Vivo Expression of Human IgG Effectively Neutralizing Pseudoviruses from HIV-1 Global Panel"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3668-6601","authenticated-orcid":false,"given":"German A.","family":"Shipulin","sequence":"first","affiliation":[{"name":"Centre for Strategic Planning and Management of Biomedical Health Risks, Federal Medical Biological Agency, 119992 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dina V.","family":"Glazkova","sequence":"additional","affiliation":[{"name":"Centre for Strategic Planning and Management of Biomedical Health Risks, Federal Medical Biological Agency, 119992 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2304-7787","authenticated-orcid":false,"given":"Felix A.","family":"Urusov","sequence":"additional","affiliation":[{"name":"Centre for Strategic Planning and Management of Biomedical Health Risks, Federal Medical Biological Agency, 119992 Moscow, Russia"},{"name":"Izmerov Research Institute of Occupational Health, 105275 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2646-9774","authenticated-orcid":false,"given":"Boris V.","family":"Belugin","sequence":"additional","affiliation":[{"name":"Centre for Strategic Planning and Management of Biomedical Health Risks, Federal Medical Biological Agency, 119992 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5702-8344","authenticated-orcid":false,"given":"Valeriya","family":"Dontsova","sequence":"additional","affiliation":[{"name":"Centre for Strategic Planning and Management of Biomedical Health Risks, Federal Medical Biological Agency, 119992 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra V.","family":"Panova","sequence":"additional","affiliation":[{"name":"Centre for Strategic Planning and Management of Biomedical Health Risks, Federal Medical Biological Agency, 119992 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4278-882X","authenticated-orcid":false,"given":"Alyona A.","family":"Borisova","sequence":"additional","affiliation":[{"name":"Centre for Strategic Planning and Management of Biomedical Health Risks, Federal Medical Biological Agency, 119992 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Galina M.","family":"Tsyganova","sequence":"additional","affiliation":[{"name":"Centre for Strategic Planning and Management of Biomedical Health Risks, Federal Medical Biological Agency, 119992 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3250-6498","authenticated-orcid":false,"given":"Elena V.","family":"Bogoslovskaya","sequence":"additional","affiliation":[{"name":"Centre for Strategic Planning and Management of Biomedical Health Risks, Federal Medical Biological Agency, 119992 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,8,14]]},"reference":[{"key":"ref_1","unstructured":"UNAIDS (2024, June 07). AIDS Statistics. Available online: https:\/\/www.unaids.org\/ru\/resources\/fact-sheet."},{"key":"ref_2","unstructured":"(2024, June 07). WHO. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hiv-drug-resistance."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/nature07930","article-title":"Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals","volume":"458","author":"Scheid","year":"2009","journal-title":"Nature"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1146\/annurev-med-061016-041032","article-title":"New-Generation High-Potency and Designer Antibodies: Role in HIV-1 Treatment","volume":"69","author":"Gama","year":"2018","journal-title":"Annu. Rev. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12977-018-0443-0","article-title":"Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers","volume":"15","author":"Landais","year":"2018","journal-title":"Retrovirology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/s41591-019-0412-8","article-title":"Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic","volume":"4","author":"Caskey","year":"2019","journal-title":"Nat. Med."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Wagh, K., Bhattacharya, T., Williamson, C., Robles, A., Bayne, M., Garrity, J., Rist, M., Rademeyer, C., Yoon, H., and Lapedes, A. (2016). Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection. PLoS Pathog., 12.","DOI":"10.1371\/journal.ppat.1005520"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Kochina, E.A., Urusov, F.A., Kruglov, A.A., Glazkova, D.V., Shipulin, G.A., and Bogoslovskaya, E.V. (2022). Double and Triple Combinations of Broadly Neutralizing Antibodies Provide Efficient Neutralization of All HIV-1 Strains from the Global Panel. Viruses, 14.","DOI":"10.3390\/v14091910"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"8769","DOI":"10.1128\/JVI.76.17.8769-8775.2002","article-title":"Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer","volume":"76","author":"Lewis","year":"2002","journal-title":"J. Virol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.immuni.2019.02.005","article-title":"Adeno-Associated Virus Delivery of Anti-HIV Monoclonal Antibodies Can Drive Long-Term Virologic Suppression","volume":"50","author":"Fuchs","year":"2019","journal-title":"Immunity"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/sj.gt.3300938","article-title":"Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield","volume":"6","author":"Zolotukhin","year":"1999","journal-title":"Gene Ther."},{"key":"ref_12","first-page":"68","article-title":"Purification of adeno-associated DJ virus by anion-exchange chromatography: Optimization of condition","volume":"39","author":"Glazkova","year":"2023","journal-title":"Biotechnology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1089\/hgtb.2011.034","article-title":"Universal real-time PCR for the detection and quantification of adeno-associated virus serotype 2-derived inverted terminal repeat sequences","volume":"23","author":"Aurnhammer","year":"2012","journal-title":"Hum. Gene Ther. Methods"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1128\/JVI.02853-13","article-title":"Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies","volume":"5","author":"Decamp","year":"2014","journal-title":"J. Virol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1134\/S0026893318020085","article-title":"Protection of Lymphocytes from HIV by Lentiviral Vector Carrying Gene Combination of TRIM5\u03b1-HRH and microRNAs against CCR5","volume":"52","author":"Omelchenko","year":"2018","journal-title":"Mol. Biol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jim.2014.02.013","article-title":"Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1","volume":"409","author":"Bailer","year":"2014","journal-title":"Immun. Methods"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/978-1-59745-170-3_26","article-title":"Measuring HIV neutralization in a luciferase reporter gene assay","volume":"485","author":"Montefiori","year":"2009","journal-title":"Methods Mol. Biol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.immuni.2016.10.027","article-title":"Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth","volume":"45","author":"Huang","year":"2016","journal-title":"Immunity"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/nature11544","article-title":"Broad and potent neutralization of HIV-1 by a gp41-specific human antibody","volume":"491","author":"Huang","year":"2012","journal-title":"Nature"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"E3268","DOI":"10.1073\/pnas.1217207109","article-title":"Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies","volume":"109","author":"Mouquet","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"12669","DOI":"10.1128\/JVI.02213-14","article-title":"Enhanced Potency of a Broadly Neutralizing HIV-1 Antibody In Vitro Improves Protection against Lentiviral Infection In Vivo","volume":"88","author":"Rudicell","year":"2014","journal-title":"J. Virol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"17624","DOI":"10.1073\/pnas.1415789111","article-title":"Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex","volume":"111","author":"Sok","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nature10660","article-title":"Antibody-based protection against HIV infection by vectored immunoprophylaxis","volume":"481","author":"Balazs","year":"2011","journal-title":"Nature"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.omtm.2019.06.002","article-title":"AAV-Mediated Expression of Broadly Neutralizing and Vaccine-like Antibodies Targeting the HIV-1 Envelope V2 Region","volume":"14","author":"Berg","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.2147\/IJN.S412915","article-title":"Combined Nano-Vector Mediated-Transfer to Suppress HIV-1 Infection with Targeted Antibodies in-vitro","volume":"18","author":"Yao","year":"2023","journal-title":"Int. J. Nanomed."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e230","DOI":"10.1016\/S2352-3018(19)30003-7","article-title":"Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: A phase 1 randomised controlled trial","volume":"6","author":"Priddy","year":"2019","journal-title":"Lancet HIV"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/s41591-022-01762-x","article-title":"Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: A phase 1, dose-escalation trial","volume":"28","author":"Casazza","year":"2022","journal-title":"Nat. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"8098","DOI":"10.1128\/jvi.70.11.8098-8108.1996","article-title":"Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector","volume":"70","author":"Xiao","year":"1996","journal-title":"J. Virol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"14082","DOI":"10.1073\/pnas.93.24.14082","article-title":"Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein","volume":"93","author":"Kessler","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Welles, H.C., Jennewein, M.F., Mason, R.D., Narpala, S., Wang, L., Cheng, C., Zhang, Y., Todd, J.-P., Lifson, J.D., and Balazs, A.B. (2018). Vectored delivery of anti-SIV envelope targeting mAb via AAV8 protects rhesus macaques from repeated limiting dose intrarectal swarm SIVsmE660 challenge. PLoS Pathog., 14.","DOI":"10.1371\/journal.ppat.1007395"},{"key":"ref_31","unstructured":"Mironov, A. (2012). Guidelines for Conducting Preclinical Studies of Drugs (Immunobiological Drugs), Part Two; Aquarium."},{"key":"ref_32","unstructured":"(2021, November 02). WHO Manual on Animal Influenza Diagnosis and Surveillance. Available online: https:\/\/www.who.int\/csr\/resources\/publications\/influenza\/whocdscsrncs20025rev.pdf."},{"key":"ref_33","unstructured":"(2021, November 02). Manual for the Laboratory Diagnosis and Virological Surveillance of Influenza, WHO Global Influenza Surveillance Network. Available online: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/44518\/9789241548090_eng.pdf?sequence=1."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/8\/1296\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:36:37Z","timestamp":1760110597000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/8\/1296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,14]]},"references-count":33,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["v16081296"],"URL":"https:\/\/doi.org\/10.3390\/v16081296","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,14]]}}}